BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37014815)

  • 1. Liver injury indicators and subsequent cancer development among non-fatty liver population.
    Ito H; Kimura T; Takuro S; Higashitani M; Yamamoto K; Kobayashi D
    Cancer Med; 2023 Jun; 12(11):12173-12186. PubMed ID: 37014815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver fibrosis scores and prognosis in patients with cardiovascular diseases: A systematic review and meta-analysis.
    Yan Z; Liu Y; Li W; Zhao X; Lin W; Zhang J; Yu S; Ma J; Wang J; Yu P; Li W; Liu X
    Eur J Clin Invest; 2022 Nov; 52(11):e13855. PubMed ID: 36001034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States.
    Kim D; Kim WR; Kim HJ; Therneau TM
    Hepatology; 2013 Apr; 57(4):1357-65. PubMed ID: 23175136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gaps in Confirmatory Fibrosis Risk Assessment in Primary Care Patients with Nonalcoholic Fatty Liver Disease.
    Moore JA; Wheless WH; Zhang J; Marsden J; Mauldin PD; Moran WP; Schreiner AD
    Dig Dis Sci; 2023 Jul; 68(7):2946-2953. PubMed ID: 37193930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced liver fibrosis and the metabolic syndrome in a primary care setting.
    Schreiner AD; Zhang J; Durkalski-Mauldin V; Livingston S; Marsden J; Bian J; Mauldin PD; Moran WP; Rockey DC
    Diabetes Metab Res Rev; 2021 Nov; 37(8):e3452. PubMed ID: 33759300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Implications of Cardiac Symptoms and Electrocardiographic Abnormalities for Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.
    Kang MK; Kim MC
    Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837575
    [No Abstract]   [Full Text] [Related]  

  • 7. Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population.
    Graupera I; Thiele M; Serra-Burriel M; Caballeria L; Roulot D; Wong GL; Fabrellas N; Guha IN; Arslanow A; Expósito C; Hernández R; Aithal GP; Galle PR; Pera G; Wong VW; Lammert F; Ginès P; Castera L; Krag A;
    Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2567-2576.e6. PubMed ID: 34971806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically Significant Fibrosis Is Associated With Longitudinal Increases in Fibrosis-4 and Nonalcoholic Fatty Liver Disease Fibrosis Scores.
    Patel PJ; Cheng JC; Banh X; Gracen L; Radford-Smith D; Hossain F; Horsfall LU; Hayward KL; Williams S; Johnson T; Brown NN; Saad N; Stuart KA; Russell AW; Valery PC; Clouston AD; Irvine KM; Bernard A; Powell EE
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):710-718.e4. PubMed ID: 31352092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrosis Risk in Nonalcoholic Fatty Liver Disease Is Related to Chronic Kidney Disease in Older Type 2 Diabetes Patients.
    Sun Y; Hong L; Huang Z; Wang L; Xiong Y; Zong S; Zhang R; Liu J; Zang S
    J Clin Endocrinol Metab; 2022 Aug; 107(9):e3661-e3669. PubMed ID: 35766414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.
    Prasoppokakorn T; Chan WK; Wong VW; Pitisuttithum P; Mahadeva S; Nik Mustapha NR; Wong GL; Leung HH; Sripongpun P; Treeprasertsuk S
    World J Gastroenterol; 2022 Apr; 28(15):1563-1573. PubMed ID: 35582126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
    Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.
    Petta S; Wai-Sun Wong V; Bugianesi E; Fracanzani AL; Cammà C; Hiriart JB; Lai-Hung Wong G; Vergniol J; Wing-Hung Chan A; Giannetti A; Merrouche W; Lik-Yuen Chan H; Le-Bail B; Lombardi R; Guastella S; Craxì A; de Ledinghen V
    Am J Gastroenterol; 2019 Jun; 114(6):916-928. PubMed ID: 31169533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
    Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
    Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
    BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepamet Fibrosis Score in Nonalcoholic Fatty Liver Disease Patients in Mexico: Lower than Expected Positive Predictive Value.
    Higuera-de-la-Tijera F; Córdova-Gallardo J; Buganza-Torio E; Barranco-Fragoso B; Torre A; Parraguirre-Martínez S; Rojano-Rodríguez ME; Quintero-Bustos G; Castro-Narro G; Moctezuma-Velazquez C
    Dig Dis Sci; 2021 Dec; 66(12):4501-4507. PubMed ID: 33428035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver fibrosis scores and atrial fibrillation incidence in heart failure with preserved ejection fraction.
    Liu X; Chen W; Shao W; Jiang Y; Cao Z; He W; Wu M; Chen Z; Ma J; Chen Y; Yu P; Zhang Y; Wang J
    ESC Heart Fail; 2022 Dec; 9(6):3985-3994. PubMed ID: 35996808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accuracy of Noninvasive Fibrosis Scoring Systems in African American and White Patients With Nonalcoholic Fatty Liver Disease.
    Marella HK; Reddy YK; Jiang Y; Ganguli S; Podila PSB; Snell PD; Kovalic AJ; Cholankeril G; Singal AK; Nair S; Maliakkal B; Satapathy SK
    Clin Transl Gastroenterol; 2020 Apr; 11(4):e00165. PubMed ID: 32352687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD.
    Xun YH; Guo JC; Lou GQ; Jiang YM; Zhuang ZJ; Zhu MF; Luo Y; Ma XJ; Liu J; Bian DX; Shi JP
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):643-9. PubMed ID: 24837195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA.
    Wijarnpreecha K; Thongprayoon C; Scribani M; Ungprasert P; Cheungpasitporn W
    Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):404-410. PubMed ID: 29215435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.